Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER MEDICAL ASSOC
Autores
SHAH, Sanjiv J.
FINE, Nowell
GARCIA-PAVIA, Pablo
KLEIN, Allan L.
WEISSMAN, Neil J.
MAURER, Mathew S.
BOMAN, Kurt
GUNDAPANENI, Balarama
SULTAN, Marla B.
Citação
JAMA CARDIOLOGY, v.9, n.1, p.25-34, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Importance Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized.Objective To examine the effect of tafamidis on cardiac function in patients with ATTR-CM.Design, Setting, and Participants This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023.Intervention Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months.Main Outcomes and Measures Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (>= 50%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (<= 40%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E/e ') were compared in patients receiving tafamidis, 80 mg, vs placebo.Results A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n = 176), vs placebo (n = 177) (least squares mean difference: LV stroke volume, 7.02 mL; 95% CI, 2.55-11.49; P = .002; LV global longitudinal strain, -1.02%; 95% CI, -1.73 to -0.31; P = .005; septal E/e ', -3.11; 95% CI, -5.50 to -0.72; P = .01; lateral E/e ', -2.35; 95% CI, -4.01 to -0.69; P = .006).Conclusions and Relevance Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.Trial Registration ClinicalTrials.gov Identifier: NCT01994889
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/59288
Referências
  1. Abou R, 2020, HEART, V106, P1438, DOI 10.1136/heartjnl-2019-316215
  2. AbouEzzeddine OF, 2021, JAMA CARDIOL, V6, P1267, DOI 10.1001/jamacardio.2021.3070
  3. Bozkurt B, 2021, J CARD FAIL, V27, P387, DOI 10.1016/j.cardfail.2021.01.022
  4. Bukhari S, 2020, CIRCULATION, V142
  5. Bulawa CE, 2012, P NATL ACAD SCI USA, V109, P9629, DOI 10.1073/pnas.1121005109
  6. Castaño A, 2015, HEART FAIL REV, V20, P163, DOI 10.1007/s10741-014-9462-7
  7. Chacko L, 2020, EUR HEART J, V41, P1439, DOI 10.1093/eurheartj/ehz905
  8. Damy T, 2021, EUR J HEART FAIL, V23, P277, DOI 10.1002/ejhf.2027
  9. Giblin GT, 2022, EUR HEART J-CARD IMG, V23, P1029, DOI 10.1093/ehjci/jeac049
  10. González-López E, 2015, EUR HEART J, V36, P2585, DOI 10.1093/eurheartj/ehv338
  11. Jacobson DR, 2015, AMYLOID, V22, P171, DOI 10.3109/13506129.2015.1051219
  12. Lane T, 2019, CIRCULATION, V140, P16, DOI 10.1161/CIRCULATIONAHA.118.038169
  13. Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014
  14. Maurer MS, 2018, NEW ENGL J MED, V379, P1007, DOI 10.1056/NEJMoa1805689
  15. Maurer MS, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.116.003815
  16. Maurer MS, 2016, J AM COLL CARDIOL, V68, P161, DOI 10.1016/j.jacc.2016.03.596
  17. Minamisawa M, 2019, JAMA CARDIOL, V4, P466, DOI 10.1001/jamacardio.2019.0849
  18. Mohty D, 2013, ARCH CARDIOVASC DIS, V106, P528, DOI 10.1016/j.acvd.2013.06.051
  19. Nagueh SF, 2016, J AM SOC ECHOCARDIOG, V29, P277, DOI 10.1016/j.echo.2016.01.011
  20. Nativi-Nicolau J, 2021, ESC HEART FAIL, V8, P3875, DOI 10.1002/ehf2.13541
  21. Pfizer, VYND TAF MEGL VYND T
  22. Phelan D, 2012, HEART, V98, P1442, DOI 10.1136/heartjnl-2012-302353
  23. Quarta CC, 2014, CIRCULATION, V129, P1840, DOI 10.1161/CIRCULATIONAHA.113.006242
  24. Rettl R, 2023, AMYLOID, V30, P127, DOI 10.1080/13506129.2022.2131385
  25. Rettl R, 2022, EUR HEART J-CARD IMG, V23, P767, DOI 10.1093/ehjci/jeab226
  26. Ruberg FL, 2019, J AM COLL CARDIOL, V73, P2872, DOI 10.1016/j.jacc.2019.04.003
  27. Shah SJ, 2019, CIRCULATION, V139, P444, DOI 10.1161/CIRCULATIONAHA.118.037593
  28. Smiseth OA, 2016, EUR HEART J, V37, P1196, DOI 10.1093/eurheartj/ehv529
  29. Witteles RM, 2019, JACC-HEART FAIL, V7, P709, DOI 10.1016/j.jchf.2019.04.010

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor